$SBFM Biotech Investor Q&A with CFO  of Sunshine Biopharma (OTCBB: SBFM)

Discussing its Lead Compound - Adva-27a for Aggressive Forms of Cancer

New York, New York - July 2, 2012 - Investorideas.com, an investor research portal specializing in sector

research including biotech and pharma stocks, issues an  exclusive Q&A interview with Mr. Camille

Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB:SBFM). Sunshine Biopharma is a pharmaceutical

company focused on the research, development and commercialization of drugs for the treatment of

various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.

Mr. Sebaaly also shares insight on Roche’s (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug.

Interview:

Q: Investorideas.com staff

Can you give investors a brief background on your lead compound, Adva-27a, your proprietary

technology behind it and how it targets aggressive forms of cancer?

A: Mr. Camille Sebaaly, CFO

Adva-27a is a small molecule which we designed and synthesized de novo.  Patents covering

Adva-27a and derivatives have been issued in the United States and Europe and are still

pending in other places around the world.  Adva-27a was designed it to specifically target

multidrug resistant (or aggressive) types of cancer.

Q: Investorideas.com staff

The Company announced findings last week from the  cytotoxicity study- can you give us

some brief hi-lights and the significance of the results?

A: Mr. Camille Sebaaly, CFO

Last week we announced the results of our most recent studies in which we found that Adva-

27a is remarkably capable of killing multidrug resistant small cell lung cancer.  Small cell lung

cancer is perhaps the most aggressive primary cancer.  Sadly, the prognosis for a freshly

diagnosed patient with small cell lung cancer is only a few months.  As you know, we had

announced back in July of last year that Adva-27a also kills multidrug resistant breast cancer

cells.  Similarly, the prognosis for multidrug resistant breast cancer patients is only a few

months.  We are delighted at the opportunity to offer both of these patient groups hope through

our Adva-27a.  As far we know, Adva-27a is the only drug anywhere in the world that can treat

these patients.

Q: Investorideas.com staff

Can you discuss briefly the pharmacokinetics studies results announced in May?

A: Mr. Camille Sebaaly, CFO

The pharmacokinetic parameters of Adva-27a which we announced in May were excellent.

Adva-27a has all the properties of a good pharmaceutical.  For example, it reaches a very high

initial plasma concentration, which means it starts working fast, and has an intermediates

plasma half-life implying that it does not linger in the blood stream to cause severe side-effects

and other complications.

Q: Investorideas.com staff

Can you give investors insight into the type of cancer Herceptin®, a drug marketed by Roche

(SIX: RO, ROG; OTCQX: RHHBY) (the world's largest biotech company) targets and where you

see Sunshine Biopharma filling the gap?

A: Mr. Camille Sebaaly, CFO

Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer

patients.  However, only about 25% of the breast cancer patients are Her2-Positive.  For the

remaining 75%, Herceptin® does not work.  This is where our Adva-27a comes in.  It is

interesting to note that Herceptin® sales are in excess of $5 billion a year.

About Sunshine Biopharma Inc. (OTCBB: SBFM)

www.sunshinebiopharma.com

SBFM Contact:

Camille Sebaaly, CFO

Sunshine Biopharma Inc.

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com